A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
We investigated the incidence of acute kidney injury (AKI) and risk factors associated with vancomycin (VAN) and piperacillin-tazobactam (TZP) combination therapy in non-intensive care unit (ICU) and ICU settings. In this single-center retrospective cohort study, adults who received VAN for ≥48 h during the period from 1 January 2016 through 31 December 2017 were included. The primary endpoint was incidence of AKI. Data from 593 adults were analyzed. The incidence of AKI was 10.6% overall, 8.0%doi:10.1272/jnms.jnms.2020_87-203 pmid:31611508 fatcat:bx33qxrkbje35crfwacr3qphfm